Markers of PI3K/Akt, ER & AR pathways and Ki67 expression in relation to tamoxifen outcome in ER plus breast cancer

被引：0
|
作者：
Campbell, C.
Mathew, J.
Ellis, I.
Finlay, P.
Green, A.
Bradbury, I.
Borgquist, S.
Elebro, K.
Politz, O.
Haegebarth, A.
Gee, J. M.
Robertson, J. F.
机构：
[1] Frontier Sci Scotland, Inverness, Scotland
[2] Peterborough City Hosp, Peterborough, Cambs, England
[3] Nottingham Univ Hosp, Nottingham, England
[4] Cardiff Univ, Cardiff, S Glam, Wales
[5] Aarhus Univ, Aarhus, Denmark
[6] Skane Univ Hosp, Malmo, Sweden
[7] Bayer, Berlin, Germany
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P2-03-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-03-02
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER plus breast cancer
    Creighton, Chad J.
    Fu, Xiaoyong
    Hennessy, Bryan T.
    Casa, Angelo J.
    Zhang, Yiqun
    Gonzalez-Angulo, Ana Maria
    Lluch, Ana
    Gray, Joe W.
    Brown, Powell H.
    Hilsenbeck, Susan G.
    Osborne, C. Kent
    Mills, Gordon B.
    Lee, Adrian V.
    Schiff, Rachel
    BREAST CANCER RESEARCH, 2010, 12 (03):
  • [42] Enrichment for PI3K Pathway Mutations in Metastatic Low Proliferative Rate ER plus Breast Cancers
    Estrada, M. V.
    Kuba, M. G.
    Giltnane, J. M.
    Balko, J. M.
    Mayer, I. A.
    Abramson, V.
    Meszoely, I.
    Vnencak-Jones, C.
    Arteaga, C. L.
    Sanders, M. E.
    MODERN PATHOLOGY, 2014, 27 : 47A - 48A
  • [43] Enrichment for PI3K Pathway Mutations in Metastatic Low Proliferative Rate ER plus Breast Cancers
    Estrada, M. V.
    Kuba, M. G.
    Giltnane, J. M.
    Balko, J. M.
    Mayo, I. A.
    Abramson, V.
    Meszoely, I.
    Vnencak-Jones, C.
    Arteaga, C. L.
    Sanders, M. E.
    LABORATORY INVESTIGATION, 2014, 94 : 47A - 48A
  • [44] A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.
    Thompson, Alastair Mark
    Hadad, Sirwan M.
    Jordan, Lee
    Roy, Pankaj
    Purdie, Colin
    Iwamoto, Takayuki
    Pusztai, Lajos
    Moulder, Stacy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Triple combination targeting ER, CDK4/6, and PI3K inhibits tumor growth in ER plus breast cancer resistant to combined fulvestrant and CDK4/6 or PI3K inhibitor.
    Karimi, Leena
    Alves, Carla L.
    Terp, Mikkel G.
    Tuttolomondo, Martina
    Ditzel, Henrik J.
    CANCER RESEARCH, 2021, 81 (13)
  • [46] ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
    Sieuwerts, Anieta M.
    Inda, Marcia A.
    Smid, Marcel
    van Ooijen, Henk
    van de Stolpe, Anja
    Martens, John W. M.
    Verhaegh, Wim F. J.
    CANCERS, 2020, 12 (04)
  • [47] The Effect of Tamoxifen on Expression of ER, PR, Cerb-B2, and ki-67 in C3H Mice Spontaneous Breast Cancer Model and The Relation with Chemotherapeutic Effect
    Xin Li
    Sishen Zhang
    Wei Liu
    Hongpu Li
    Cell Biochemistry and Biophysics, 2014, 70 : 1875 - 1879
  • [48] The Effect of Tamoxifen on Expression of ER, PR, Cerb-B2, and ki-67 in C3H Mice Spontaneous Breast Cancer Model and The Relation with Chemotherapeutic Effect
    Li, Xin
    Zhang, Sishen
    Liu, Wei
    Li, Hongpu
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2014, 70 (03) : 1875 - 1879
  • [49] ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer
    Jin Wang
    Chao Zhang
    Keming Chen
    Hailin Tang
    Jun Tang
    Cailu Song
    Xiaoming Xie
    Breast Cancer Research and Treatment, 2015, 152 : 255 - 269
  • [50] Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
    Saini, Kamal S.
    Loi, Sherene
    de Azambuja, Evandro
    Metzger-Filho, Otto
    Saini, Monika Lamba
    Ignatiadis, Michail
    Dancey, Janet E.
    Piccart-Gebhart, Martine J.
    CANCER TREATMENT REVIEWS, 2013, 39 (08) : 935 - 946
12345